
Thomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Prior to BTIG, Mr. Shrader was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.
BackCoverage Area
Company | Ticker |
---|---|
Gain Therapeutics, Inc. | GANX |
Biogen, Inc. | BIIB |
Denali Therapeutics Inc. | DNLI |
Esperion Therapeutics, Inc. | ESPR |
Verona Pharma plc | VRNA |
Alector Inc. | ALEC |
Stoke Therapeutics, Inc. | STOK |
BridgeBio Pharma, Inc. | BBIO |
INmune Bio Inc. | INMB |
Aldeyra Therapeutics | ALDX |
Silence Therapeutics | SLN |
Seelos Therapeutics, Inc. | SEEL |
Pliant Therapeutics | PLRX |
Celularity | CELU |
COMPASS Pathways plc | CMPS |
Athira Pharma | ATHA |
Acumen Pharmaceuticals | ABOS |
Vaxcyte, Inc. | PCVX |
Biohaven Ltd. | BHVN |
Coya Therapeutics, Inc. | COYA |
ProMIS Neurosciences Inc. | PMN |